Artal Group
Latest statistics and disclosures from Artal Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LXRX, WW, BGNE, MRTX, ARGX, and represent 27.64% of Artal Group's stock portfolio.
- Added to shares of these 10 stocks: FCX (+$90M), Erasca (+$67M), SGEN (+$64M), MRTX (+$62M), Omega Therapeutics (+$43M), MRK (+$38M), VRTX (+$36M), CYTK (+$29M), FOLD (+$28M), PTGX (+$27M).
- Started 19 new stock positions in EQT, Erasca, Omega Therapeutics, AVTR, PTGX, MRK, BABA, WVE, CRVS, AMYT. Caribou Biosciences, Astria Therapeutics, ATUS, Olaplex Hldgs, SGEN, GDS, Hippo Holdings, Portage Fintech Acquisitio-a, VRTX.
- Reduced shares in these 10 stocks: GM (-$118M), BGNE (-$73M), Acceleron Pharma (-$69M), INTC (-$53M), C (-$53M), F (-$52M), BHVN (-$39M), SEER (-$29M), Trillium Therapeutics, Inc. Cmn (-$24M), CAR (-$23M).
- Sold out of its positions in AGL, ALDX, CAR, BHG, CEREW, Chiasma, F, GM, LFST, LU. MOLN, MCRB, Translate Bio, Trillium Therapeutics, Inc. Cmn, VIAC, BHVN, DLO.
- Artal Group was a net seller of stock by $-45M.
- Artal Group has $4.5B in assets under management (AUM), dropping by -9.29%.
- Central Index Key (CIK): 0001053906
Tip: Access up to 7 years of quarterly data
Positions held by Artal Group consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Artal Group
Companies in the Artal Group portfolio as of the September 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals Com New (LXRX) | 7.7 | $342M | 71M | 4.81 | ||
| Ww Intl (WW) | 6.1 | $270M | 15M | 18.25 | ||
| Beigene Sponsored Adr (BGNE) | 5.3 | $236M | -23% | 650k | 363.00 | |
| Mirati Therapeutics (MRTX) | 4.7 | $212M | +41% | 1.2M | 176.91 | |
| Argenx Se Sponsored Adr (ARGX) | 3.9 | $174M | +15% | 577k | 302.00 | |
| Acceleron Pharma | 3.9 | $172M | -28% | 1.0M | 172.10 | |
| Seer Com Cl A (SEER) | 3.7 | $164M | -15% | 4.8M | 34.53 | |
| Citigroup Com New Call Option (C) | 3.1 | $140M | -27% | 2.0M | 70.18 | |
| Alnylam Pharmaceuticals (ALNY) | 3.0 | $132M | -6% | 700k | 188.81 | |
| Freeport-mcmoran CL B Call Option (FCX) | 2.5 | $114M | +366% | 3.5M | 32.53 | |
| Morphic Hldg (MORF) | 2.0 | $90M | -12% | 1.6M | 56.64 | |
| Igm Biosciences (IGMS) | 2.0 | $89M | +22% | 1.4M | 65.76 | |
| Fate Therapeutics (FATE) | 1.9 | $86M | +7% | 1.5M | 59.27 | |
| Rubius Therapeutics (RUBY) | 1.7 | $74M | -10% | 4.2M | 17.88 | |
Setup an alertArtal Group will file the next quarterly 13-HR in about 1 months. Would you like to be notified? |
||||||
| Generation Bio (GBIO) | 1.6 | $71M | 2.8M | 25.07 | ||
| Erasca | 1.5 | $67M | NEW | 3.2M | 21.22 | |
| Scholar Rock Hldg Corp (SRRK) | 1.4 | $64M | -2% | 2.0M | 33.02 | |
| Amicus Therapeutics (FOLD) | 1.4 | $64M | +78% | 6.7M | 9.55 | |
| Seagen (SGEN) | 1.4 | $64M | NEW | 375k | 169.80 | |
| I Mab Sponsored Ads (IMAB) | 1.3 | $60M | +10% | 825k | 72.49 | |
| Bristol Myers Squibb Call Option (BMY) | 1.3 | $59M | 1.0M | 59.17 | ||
| Allovir (ALVR) | 1.3 | $58M | 2.3M | 25.06 | ||
| Cerevel Therapeutics Hldng I (CERE) | 1.2 | $53M | -10% | 1.8M | 29.50 | |
| Cytokinetics Com New (CYTK) | 1.0 | $47M | +160% | 1.3M | 35.74 | |
| Sage Therapeutics (SAGE) | 1.0 | $44M | 1.0M | 44.31 | ||
| Omega Therapeutics | 1.0 | $43M | NEW | 2.3M | 18.85 | |
| Schrodinger (SDGR) | 0.9 | $38M | -12% | 700k | 54.68 | |
| Springworks Therapeutics (SWTX) | 0.9 | $38M | +20% | 600k | 63.44 | |
| Merck & Co Call Option (MRK) | 0.8 | $38M | NEW | 500k | 75.11 | |
| Alx Oncology Hldgs (ALXO) | 0.8 | $37M | 500k | 73.86 | ||
| Intellia Therapeutics (NTLA) | 0.8 | $37M | +10% | 275k | 134.15 | |
| Vertex Pharmaceuticals Incorporated Call Option (VRTX) | 0.8 | $36M | NEW | 200k | 181.39 | |
| Bellus Health Com New (BLU) | 0.7 | $32M | +10% | 5.3M | 6.14 | |
| Gossamer Bio (GOSS) | 0.7 | $30M | 2.4M | 12.57 | ||
| Agenus Com New (AGEN) | 0.6 | $29M | -8% | 5.5M | 5.25 | |
| Talaris Therapeutics (TALS) | 0.6 | $28M | 2.1M | 13.56 | ||
| Kronos Bio (KRON) | 0.6 | $28M | 1.3M | 20.96 | ||
| Atara Biotherapeutics (ATRA) | 0.6 | $27M | 1.5M | 17.90 | ||
| Iteos Therapeutics (ITOS) | 0.6 | $27M | 994k | 27.00 | ||
| Replimune Group (REPL) | 0.6 | $27M | 900k | 29.64 | ||
| Tg Therapeutics (TGTX) | 0.6 | $27M | 800k | 33.28 | ||
| Protagonist Therapeutics (PTGX) | 0.6 | $27M | NEW | 1.5M | 17.72 | |
| Krystal Biotech (KRYS) | 0.6 | $26M | 500k | 52.21 | ||
| Denali Therapeutics (DNLI) | 0.6 | $25M | 500k | 50.45 | ||
| Foghorn Therapeutics (FHTX) | 0.5 | $24M | 1.7M | 13.93 | ||
| Kymera Therapeutics (KYMR) | 0.5 | $24M | +60% | 400k | 58.74 | |
| Turning Point Therapeutics I (TPTX) | 0.5 | $23M | 350k | 66.43 | ||
| Forma Therapeutics Hldgs SHS (FMTX) | 0.5 | $23M | 1.0M | 23.19 | ||
| Sqz Biotech (SQZ) | 0.5 | $23M | 1.6M | 14.42 | ||
| Oatly Group Ab Sponsored Ads (OTLY) | 0.5 | $23M | 1.5M | 15.12 | ||
| Praxis Precision Medicines I (PRAX) | 0.5 | $22M | 1.2M | 18.49 | ||
| Aurinia Pharmaceuticals (AUPH) | 0.5 | $22M | 1.0M | 22.13 | ||
| Kura Oncology (KURA) | 0.4 | $20M | +75% | 1.1M | 18.73 | |
| Ikena Oncology (IKNA) | 0.4 | $20M | 1.5M | 12.62 | ||
| Taysha Gene Therapies Com Shs (TSHA) | 0.4 | $19M | 1.0M | 18.62 | ||
| Verve Therapeutics (VERV) | 0.4 | $19M | -20% | 400k | 47.00 | |
| Albireo Pharma (ALBO) | 0.4 | $19M | 600k | 31.20 | ||
| Neximmune (NEXI) | 0.4 | $18M | 1.2M | 15.14 | ||
| Novagold Res Com New (NG) | 0.4 | $18M | 2.6M | 6.88 | ||
| Achilles Therapeutics Sponsored Ads (ACHL) | 0.4 | $18M | 2.3M | 7.79 | ||
| Selecta Biosciences (SELB) | 0.4 | $17M | 4.0M | 4.16 | ||
| Leap Therapeutics (LPTX) | 0.4 | $16M | +33% | 4.0M | 4.01 | |
| Intel Corporation Call Option (INTC) | 0.4 | $16M | -76% | 300k | 53.28 | |
| Alibaba Group Hldg Sponsored Ads (BABA) | 0.3 | $15M | NEW | 100k | 148.05 | |
| Repare Therapeutics Ord (RPTX) | 0.3 | $14M | 550k | 26.24 | ||
| Adagene Ads (ADAG) | 0.3 | $14M | 1.0M | 14.37 | ||
| Aptinyx (APTX) | 0.3 | $14M | 6.1M | 2.34 | ||
| Dicerna Pharmaceuticals (DRNA) | 0.3 | $14M | -12% | 700k | 20.16 | |
| Black Diamond Therapeutics (BDTX) | 0.3 | $14M | 1.6M | 8.46 | ||
| Zymeworks (ZYME) | 0.3 | $13M | 450k | 29.04 | ||
| Relay Therapeutics (RLAY) | 0.3 | $13M | 400k | 31.53 | ||
| Bridgebio Pharma (BBIO) | 0.3 | $12M | -9% | 250k | 46.87 | |
| Ambrx Biopharma Sponsored Ads (AMAM) | 0.3 | $12M | 850k | 13.50 | ||
| Graphite Bio (GRPH) | 0.3 | $12M | 700k | 16.39 | ||
| Y Mabs Therapeutics (YMAB) | 0.3 | $11M | 400k | 28.54 | ||
| Marinus Pharmaceuticals Com New (MRNS) | 0.3 | $11M | 1.0M | 11.38 | ||
| Nanobiotix Sa Sponsored Ads (NBTX) | 0.3 | $11M | 1.0M | 11.36 | ||
| Mersana Therapeutics (MRSN) | 0.3 | $11M | 1.2M | 9.43 | ||
| Lyell Immunopharma (LYEL) | 0.2 | $10M | 700k | 14.80 | ||
| Blueprint Medicines (BPMC) | 0.2 | $10M | 100k | 102.81 | ||
| Curis Com New (CRIS) | 0.2 | $10M | 1.3M | 7.83 | ||
| Caribou Biosciences | 0.2 | $9.7M | NEW | 405k | 23.87 | |
| Spero Therapeutics (SPRO) | 0.2 | $9.2M | 500k | 18.41 | ||
| Sana Biotechnology (SANA) | 0.2 | $9.0M | 400k | 22.52 | ||
| Syros Pharmaceuticals (SYRS) | 0.2 | $8.9M | +17% | 2.0M | 4.47 | |
| Vor Biopharma (VOR) | 0.2 | $8.6M | 550k | 15.68 | ||
| Cyclerion Therapeutics (CYCN) | 0.2 | $8.5M | 2.8M | 3.07 | ||
| Dyne Therapeutics (DYN) | 0.2 | $8.5M | 525k | 16.24 | ||
| Ovid Therapeutics (OVID) | 0.2 | $8.4M | 2.5M | 3.36 | ||
| Oric Pharmaceuticals (ORIC) | 0.2 | $8.4M | 400k | 20.91 | ||
| Aeglea Biotherapeutics (AGLE) | 0.2 | $8.3M | 1.0M | 7.95 | ||
| Instil Bio (TIL) | 0.2 | $8.0M | 450k | 17.88 | ||
| Iqiyi Sponsored Ads (IQ) | 0.2 | $8.0M | 1.0M | 8.03 | ||
| Harpoon Therapeutics (HARP) | 0.2 | $7.9M | 1.0M | 7.90 | ||
| Immunocore Hldgs Ads (IMCR) | 0.2 | $7.4M | 200k | 37.07 | ||
| Omega Alpha Spac Cl A (OMEG) | 0.2 | $7.3M | 750k | 9.73 | ||
| Olema Pharmaceuticals (OLMA) | 0.2 | $7.2M | 261k | 27.56 | ||
| Solid Biosciences (SLDB) | 0.2 | $7.2M | +33% | 3.0M | 2.39 | |
| Evelo Biosciences (EVLO) | 0.2 | $7.0M | 1.0M | 7.04 | ||
| Ac Immune Sa SHS (ACIU) | 0.2 | $6.7M | 1.0M | 6.71 | ||
| Applied Therapeutics (APLT) | 0.1 | $6.6M | 400k | 16.60 | ||
| Adverum Biotechnologies (ADVM) | 0.1 | $6.5M | 3.0M | 2.17 | ||
| Tcr2 Therapeutics Inc cs (TCRR) | 0.1 | $6.4M | 750k | 8.51 | ||
| Stoke Therapeutics (STOK) | 0.1 | $6.4M | 250k | 25.44 | ||
| Alpine Immune Sciences (ALPN) | 0.1 | $6.3M | 593k | 10.67 | ||
| Immunic (IMUX) | 0.1 | $6.2M | 700k | 8.85 | ||
| Contrafect Corp Com New (CFRX) | 0.1 | $6.1M | 1.5M | 4.05 | ||
| 111 Ads (YI) | 0.1 | $6.0M | 966k | 6.17 | ||
| Fusion Pharmaceuticals (FUSN) | 0.1 | $5.9M | 750k | 7.92 | ||
| Design Therapeutics (DSGN) | 0.1 | $5.9M | 400k | 14.69 | ||
| GDS HLDGS Sponsored Ads (GDS) | 0.1 | $5.7M | NEW | 100k | 56.61 | |
| Olaplex Hldgs | 0.1 | $5.5M | NEW | 225k | 24.50 | |
| Cardiff Oncology (CRDF) | 0.1 | $5.0M | 750k | 6.66 | ||
| Dynamics Special Purpose Cor Class A Com (DYNS) | 0.1 | $5.0M | 500k | 9.94 | ||
| Wave Life Sciences SHS (WVE) | 0.1 | $4.9M | NEW | 1.0M | 4.90 | |
| Aravive (ARAV) | 0.1 | $4.9M | 1.3M | 3.72 | ||
| Recursion Pharmaceuticals In Cl A (RXRX) | 0.1 | $4.6M | 200k | 23.01 | ||
| Orchard Therapeutics Ads (ORTX) | 0.1 | $4.1M | 1.8M | 2.30 | ||
| Immutep Sponsored Ads (IMMP) | 0.1 | $3.9M | 1.0M | 3.87 | ||
| Portage Fintech Acquisitn Class A Ord Shs | 0.1 | $3.8M | NEW | 380k | 10.00 | |
| Mereo Biopharma Group Ads (MREO) | 0.1 | $3.6M | 1.5M | 2.42 | ||
| Hookipa Pharma Inc equity (HOOK) | 0.1 | $3.5M | 600k | 5.89 | ||
| Avidity Biosciences Ord (RNA) | 0.1 | $3.5M | 143k | 24.63 | ||
| Deciphera Pharmaceuticals (DCPH) | 0.1 | $3.4M | -50% | 100k | 33.98 | |
| Codiak Biosciences (CDAK) | 0.1 | $3.3M | 200k | 16.33 | ||
| Metacrine Ord (MTCR) | 0.1 | $3.2M | 925k | 3.43 | ||
| Kinnate Biopharma (KNTE) | 0.1 | $2.9M | 125k | 23.02 | ||
| Hippo Holdings | 0.1 | $2.8M | NEW | 600k | 4.68 | |
| Mei Pharma Com New (MEIP) | 0.1 | $2.8M | 1.0M | 2.76 | ||
| Kaleido Biosciences Ord (KLDO) | 0.1 | $2.7M | 501k | 5.46 | ||
| Corvus Pharmaceuticals (CRVS) | 0.1 | $2.4M | NEW | 500k | 4.84 | |
| Chinook Therapeutics (KDNY) | 0.1 | $2.3M | 181k | 12.76 | ||
| Cullinan Oncology (CGEM) | 0.1 | $2.3M | 100k | 22.57 | ||
| Yumanity Therapeutics (YMTX) | 0.1 | $2.2M | 217k | 10.32 | ||
| Axcella Health Inc equity (AXLA) | 0.0 | $2.1M | 713k | 2.98 | ||
| Avantor (AVTR) | 0.0 | $2.0M | NEW | 50k | 40.90 | |
| Amryt Pharma Sponsored Ads (AMYT) | 0.0 | $1.8M | NEW | 151k | 12.05 | |
| Sigilon Therapeutics (SGTX) | 0.0 | $1.6M | 276k | 5.65 | ||
| Ironwood Pharmaceuticals Com Cl A (IRWD) | 0.0 | $1.4M | 111k | 13.06 | ||
| Lava Therapeutics Nv SHS (LVTX) | 0.0 | $1.2M | 200k | 5.92 | ||
| Rigel Pharmaceuticals Com New (RIGL) | 0.0 | $1.2M | 321k | 3.63 | ||
| Surface Oncology (SURF) | 0.0 | $757k | 100k | 7.57 | ||
| Altice Usa Cl A (ATUS) | 0.0 | $559k | NEW | 27k | 20.70 | |
| Cidara Therapeutics Inc Common Stock Usd 0.0001 (CDTX) | 0.0 | $503k | 225k | 2.24 | ||
| Astria Therapeutics | 0.0 | $295k | NEW | 33k | 8.85 | |
| EQT Corporation (EQT) | 0.0 | $198k | NEW | 9.7k | 20.46 | |
Past Filings by Artal Group
SEC 13F filings are viewable for Artal Group going back to 2012
- Artal Group 2021 Q3 filed Nov. 12, 2021
- Artal Group 2021 Q2 filed Aug. 13, 2021
- Artal Group 2021 Q1 filed May 14, 2021
- Artal Group 2020 Q4 filed Feb. 11, 2021
- Artal Group 2020 Q3 filed Nov. 13, 2020
- Artal Group 2020 Q2 filed Aug. 14, 2020
- Artal Group 2020 Q1 filed May 14, 2020
- Artal Group 2019 Q4 filed Feb. 13, 2020
- Artal Group 2019 Q3 filed Nov. 14, 2019
- Artal Group 2019 Q2 filed Aug. 9, 2019
- Artal Group 2019 Q1 filed May 10, 2019
- Artal Group 2018 Q4 filed Feb. 11, 2019
- Artal Group 2018 Q3 filed Nov. 9, 2018
- Artal Group 2018 Q2 filed Aug. 10, 2018
- Artal Group 2018 Q1 filed May 10, 2018
- Artal Group 2017 Q4 filed Feb. 9, 2018